Who Paid My Doc
Golnaz Moazami
Neuro-ophthalmology New York, NY Medical Doctor
NPI 1427075407 CMS profile 944703
880 3Rd Ave, Fl 2, New York, NY 10022
General payments
$140
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Golnaz Moazami of New York, NY is reported in the CMS Open Payments database as having received $140 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 22nd percentile of Neuro-ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $62 | 1 | |
| 2023 | General | $18 | 1 | |
| 2020 | General | $60 | 1 |
Beside peers
- Golnaz Moazami
- Neuro-ophthalmology median
- Middle half of Neuro-ophthalmology
- National median
In program year 2025, general payments to Golnaz Moazami were reported at $62. Among 114 Neuro-ophthalmology profiles paid that year, the median was $182 and the middle half received between $62 and $718.
Show as a table
| Year | Golnaz Moazami | Neuro-ophthalmology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $337 | $122–$1,323 | $163 |
| 2020 | $60 | $156 | $60–$1,441 | $114 |
| 2021 | $0 | $278 | $121–$1,103 | $132 |
| 2022 | $0 | $220 | $75–$1,577 | $149 |
| 2023 | $18 | $214 | $65–$1,162 | $160 |
| 2024 | $0 | $186 | $90–$1,341 | $164 |
| 2025 | $62 | $182 | $62–$718 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 29 drugsPart D claims
1,570
Drug cost
$306,371
Branded share of claims
38.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Restasis Cyclosporine | Brand | 121 | $101,078 | |
| Lumigan Bimatoprost | Brand | 67 | $36,943 | |
| Combigan Brimonidine Tartrate/Timolol | Brand | 45 | $23,084 | |
| Cequa Cyclosporine | Brand | 32 | $18,545 | |
| Vyzulta Latanoprostene Bunod | Brand | 21 | $13,707 | |
| Alphagan P Brimonidine Tartrate | Brand | 33 | $13,380 | |
| Simbrinza Brinzolamide/Brimonidine Tart | Brand | 56 | $13,151 | |
| Xiidra Lifitegrast | Brand | 17 | $12,675 | |
| Miebo Perfluorohexyloctane/Pf | Brand | 15 | $11,502 | |
| Rocklatan Netarsudil Mesylat/Latanoprost | Brand | 18 | $10,867 |
The 10 drugs with the highest cost, of 29 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 37 billing codesPaid by Medicare
$406,577
Medicare patients
1,464
Services billed
7,578
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 65% | |
| Arthritis | 49% | |
| Osteoporosis | 30% | |
| Ischemic heart disease | 24% | |
| Diabetes | 23% | |
| Cancer | 22% | |
| Depression | 17% | |
| Chronic kidney disease | 14% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neuro-ophthalmology in New York
Mohammad Fouladvand
Neuro-ophthalmology · New York, NY
Mohammed Uddin
Neuro-ophthalmology · New York, NY
Manijeh Contractor
Neuro-ophthalmology · Albany, NY
Andrew Silverman
Neuro-ophthalmology · New York, NY
Bokkwan Jun
Neuro-ophthalmology · Flushing, NY
Daniel Elefant
Neuro-ophthalmology · Hawthorne, NY
Related records
Neuro-ophthalmology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Neuro-ophthalmology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.